Login with Linked

Follow us on

Link Linkedin Youtube

Beyfortus

Beyfortus is a single-dose antibody given to newborns and infants to prevent serious RSV (respiratory syncytial virus) lung infections during their first two RSV seasons. It reduces hospitalizations by about 70 to 80%.

Molecule Details :

  • Molecule Name :

    Nirsevimab-Alip

  • Innovator :

    SANOFI

  • Approval Date :

    17-Jul-23

  • Data Exclusivity Expiry :

    17-Jul-27

  • Market Exclusivity Expiry :

    17-Jul-35

  • Dosage Form :

    Intramuscular Injection

  • Strength :

    100mg/ 1ml and 50mg/ 0.5ml

  • Therapeutic Category :

    Antiviral

  • Revenue ($M) :

    2,346

Year-wise Projected Sales ($M) :

  • 2025 :

    2,606

  • 2026 :

    2,914

  • 2027 :

    3,168

  • 2028 :

    3,382

  • 2029 :

    3,536

  • 2030 :

    3,699

  • 2031 :

    3,862
Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.
Request a Quote

Why Choose Spring Bio Solution?

Supported 1000+ Clinical Trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO Services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions 


Schedule a Call With Us
Login with Linked

Follow us on

Linkedin Youtube Link

Login NCE Grid

Register NCE Grid

Are you sure want to logout from NCE Grid?

Not Now
Logout
Need your comparator insight?